AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11772251 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 0
Study 11772251 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG infusions
Number of subjects: 0
Study 11772251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine and vidarabine
Number of subjects: 0
Study 11772251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin and IFN‐alpha
Number of subjects: 0
Study 11772251 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha
Number of subjects: 0
Study 11772251 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulphamethoxazole
Number of subjects: 0
Study 11772251 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide, colchicine, and dapsone
Number of subjects: 0
Study 11772251 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐lymphocytic monoclonal antibodies
Number of subjects: 0
Study 11772251 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 11772251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow and stem cell transplantation
Number of subjects: 0
Study 9647022 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day quadruple therapy (omeprazole 40 mg b.i.d., amoxicillin 2.5 g once daily, metronidazole 500 mg t.i.d., bismuth subcitrate 360 mg t.i.d. for 2 days, followed by omeprazole 20 mg once daily for 6 additional days)
Number of subjects: 81
Study 9647022 — intervention group
Group type: COMPARATOR
Intervention: 14-day triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1 g t.i.d., metronidazole 500 mg t.i.d.)
Number of subjects: 81
Study 9647022 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day quadruple therapy (per-protocol analysis)
Number of subjects: 81
Study 9110943 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy in combination with other treatments
Number of subjects: 24
Study 9110943 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy
Number of subjects: 24
Study 9110943 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 24
Study 2038187 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement fixation assay (CFA)
Number of subjects: 8
Study 2038187 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 8
Study 2038187 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blot (WB)
Number of subjects: 8
Study 31036601 — intervention group
Group type: EXPERIMENTAL
Intervention: 35000HP
Number of subjects: 8
Study 31036601 — intervention group
Group type: COMPARATOR
Intervention: FX548
Number of subjects: 8
Study 29071915 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with acupoint application
Number of subjects: 62
Study 29071915 — intervention group
Group type: COMPARATOR
Intervention: Medication (Budesonide Powder)
Number of subjects: 62
Study 23410885 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU/week oral vitamin D3 for 12 weeks
Number of subjects: 30
Study 23410885 — intervention group
Group type: EXPERIMENTAL
Intervention: 40,000 IU/week oral vitamin D3 for 12 weeks
Number of subjects: 30
Study 23410885 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 30
Study 21330385 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Face Mask (TFM)
Number of subjects: 60
Study 21330385 — intervention group
Group type: COMPARATOR
Intervention: Standard Oronasal Mask (ONM)
Number of subjects: 60
Study 19167635 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valvotomy (PMV)
Number of subjects: 40
Study 19167635 — intervention group
Group type: COMPARATOR
Intervention: Closed surgical commissurotomy (CSC)
Number of subjects: 40
Study 16710109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral perfusion SPECT with [(123)I]iodoamphetamine
Number of subjects: 20
Study 14985215 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg zeaxanthin
Number of subjects: 20
Study 14985215 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zeaxanthin
Number of subjects: 20
Study 14985215 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg and 10 mg zeaxanthin
Number of subjects: 20
Study 11449612 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible asthma control plan (ATACO)
Number of subjects: 8000
Study 11449612 — intervention group
Group type: COMPARATOR
Intervention: Conventional fixed-dose management (group B)
Number of subjects: 8000
Study 9072854 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cardiac output measurements (CCO)
Number of subjects: 20
Study 9072854 — intervention group
Group type: COMPARATOR
Intervention: Bolus thermodilution cardiac output determinations (BCO)
Number of subjects: 20
Study 8448887 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide pure powder (400 micrograms)
Number of subjects: 60
Study 8448887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2946609 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaseous tubal insufflation
Number of subjects: 393
Study 2946609 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 393
Study 2946609 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 393
Study 2946609 — intervention group
Group type: COMPARATOR
Intervention: Gaseous tubal insufflation vs HSG
Number of subjects: 393
Study 2946609 — intervention group
Group type: COMPARATOR
Intervention: Gaseous tubal insufflation vs laparoscopy
Number of subjects: 393
Study 2946609 — intervention group
Group type: COMPARATOR
Intervention: HSG and laparoscopy
Number of subjects: 393
Study 29246678 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis Prevention and Self-Management Course (OPSMC)
Number of subjects: 470
Study 29246678 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (feedback of fracture risk)
Number of subjects: 470
Study 29246678 — intervention group
Group type: COMPARATOR
Intervention: Osteoporosis information leaflet (control)
Number of subjects: 470
Study 27386010 — intervention group
Group type: EXPERIMENTAL
Intervention: LED activation of 35% hydrogen peroxide and 10% carbamide peroxide
Number of subjects: 18
Study 27386010 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser activation of 35% hydrogen peroxide and 10% carbamide peroxide
Number of subjects: 18
Study 24772521 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg)
Number of subjects: 1758
Study 22653382 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly for 24 weeks (etanercept/etanercept group)
Number of subjects: 77
Study 22653382 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg once weekly for 12 weeks (placebo/etanercept group)
Number of subjects: 77
Study 20981351 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 0
Study 20981351 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocapril
Number of subjects: 0
Study 20981351 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18028521 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotics Anonymous/Alcoholics Anonymous attendance
Number of subjects: 142
Study 16103252 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing in the slow VT zone (101 to 148 bpm)
Number of subjects: 374
Study 16103252 — intervention group
Group type: COMPARATOR
Intervention: Monitoring group with no therapy in the slow VT zone
Number of subjects: 374
Study 11815318 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) 400 microg daily
Number of subjects: 160
Study 11815318 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Methyltetrahydrofolate (MTHF) 480 microg daily
Number of subjects: 160
Study 11815318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 10078538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (20, 40, and 80 mg)
Number of subjects: 0
Study 10078538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil (100, 150, and 200 mg)
Number of subjects: 0
Study 10078538 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial artery infusion of sildenafil (up to 300 microg/min)
Number of subjects: 0
Study 10078538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (40 mg) in men with ischemic heart disease
Number of subjects: 0
Study 7672465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 102
Study 7672465 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 102
Study 7672465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (rectally administered)
Number of subjects: 102
Study 1932612 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg SR oxprenolol once every 24 h
Number of subjects: 12
Study 1932612 — intervention group
Group type: COMPARATOR
Intervention: 80 mg RR oxprenolol once every 12 h
Number of subjects: 12
Study 7073917 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoperidine analgesia
Number of subjects: 41
Study 7073917 — intervention group
Group type: COMPARATOR
Intervention: Extradural analgesia with 0.5% bupivacaine with adrenaline 1:200 000
Number of subjects: 41
Study 7073917 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative blood loss
Number of subjects: 41
Study 31611499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine intraluminal administration in group A (no-touch SVG)
Number of subjects: 59
Study 31611499 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine intraluminal administration in group B (conventional preparation)
Number of subjects: 59
Study 31266825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue group offered a blood test after 12 weeks of FIT nonparticipation
Number of subjects: 1800
Study 31266825 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group given the option to choose a blood test instead of FIT at baseline
Number of subjects: 1800
Study 31266825 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional intervention)
Number of subjects: 1800
Study 31266825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue group
Number of subjects: 1800
Study 31266825 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group
Number of subjects: 1800
Study 31266825 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT test awareness
Number of subjects: 1800
Study 31266825 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood test awareness
Number of subjects: 1800
Study 29294552 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalographic biofeedback therapy
Number of subjects: 52
Study 29294552 — intervention group
Group type: COMPARATOR
Intervention: Drugs to promote the metabolism of brain cells (Control)
Number of subjects: 52
Study 25660759 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (10% O2)
Number of subjects: 22
Study 25660759 — intervention group
Group type: COMPARATOR
Intervention: Sham (21% O2)
Number of subjects: 22
Study 24054383 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile block
Number of subjects: 159
Study 24054383 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block
Number of subjects: 159
Study 24054383 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paracetamol
Number of subjects: 159
Study 22051739 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV screening
Number of subjects: 25061
Study 22051739 — intervention group
Group type: COMPARATOR
Intervention: Cervical cytology
Number of subjects: 25061
Study 19786134 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 19786134 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin chemoprophylaxis
Number of subjects: 0
Study 19786134 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BCG vaccination and rifampicin prophylaxis
Number of subjects: 0
Study 18269772 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 18269772 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 15470624 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed group (n=257)
Number of subjects: 501
Study 15470624 — intervention group
Group type: COMPARATOR
Intervention: Uninformed group (n=244)
Number of subjects: 501
Study 11469941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-packed chloroquine tablets
Number of subjects: 299
Study 11469941 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine syrup
Number of subjects: 299
Study 10077773 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT/ABPC 3 g i.v., b.i.d.
Number of subjects: 68
Study 10077773 — intervention group
Group type: COMPARATOR
Intervention: CTM 1 g i.v., b.i.d.
Number of subjects: 68
Study 8041543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental calculation
Number of subjects: 22
Study 8041543 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise
Number of subjects: 22
Study 8041543 — intervention group
Group type: COMPARATOR
Intervention: Control (no stress)
Number of subjects: 22
Study 3258429 — intervention group
Group type: EXPERIMENTAL
Intervention: High voltage electrical stimulation (daily from a commercial high voltage generator)
Number of subjects: 16
Study 3258429 — intervention group
Group type: COMPARATOR
Intervention: Control (electrodes applied daily but no stimulation)
Number of subjects: 16
Study 30849106 — intervention group
Group type: EXPERIMENTAL
Intervention: NMD-12 screening model
Number of subjects: 0
Study 28481241 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib plus lomustine
Number of subjects: 158
Study 28481241 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib
Number of subjects: 158
Study 28481241 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib monotherapy
Number of subjects: 158
Study 28481241 — intervention group
Group type: EXPERIMENTAL
Intervention: T-regulatory cell compartment
Number of subjects: 158
Study 28481241 — intervention group
Group type: COMPARATOR
Intervention: Placebo + lomustine
Number of subjects: 158
Study 28481241 — intervention group
Group type: COMPARATOR
Intervention: Lomustine monotherapy
Number of subjects: 158
Study 26202881 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin supplementation (2 mg for 4 consecutive nights)
Number of subjects: 12
Study 26202881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26202881 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin supplementation
Number of subjects: 12
Study 23787118 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt (200 g/day)
Number of subjects: 65
Study 23787118 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt (200 g/day)
Number of subjects: 65
Study 21667323 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving education (PSE)
Number of subjects: 50
Study 21667323 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 18155491 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)2) placement after irrigation with 3 mL 17% EDTA and 10 mL 6% sodium hypochlorite (NaOCl)
Number of subjects: 80
Study 18155491 — intervention group
Group type: COMPARATOR
Intervention: Control group irrigated with 10 mL 0.9% saline
Number of subjects: 80
Study 18155491 — intervention group
Group type: COMPARATOR
Intervention: Control group irrigated with 10 mL 6% sodium hypochlorite (NaOCl)
Number of subjects: 80
Study 18155491 — intervention group
Group type: COMPARATOR
Intervention: Control group irrigated with 3 mL 17% ethylenediaminetetraacetic acid (EDTA) followed by 10 mL 6% NaOCl
Number of subjects: 80
Study 18155491 — intervention group
Group type: COMPARATOR
Intervention: Control group irrigated with 1 mL 17% EDTA followed by 10 mL 6% NaOCl
Number of subjects: 80
Study 17063640 — intervention group
Group type: EXPERIMENTAL
Intervention: New ibuprofen preparation (400 mg)
Number of subjects: 23
Study 17063640 — intervention group
Group type: COMPARATOR
Intervention: Reference ibuprofen preparation (400 mg)
Number of subjects: 23
Study 14668079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose labetalol (200 mg)
Number of subjects: 9
Study 14668079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose labetalol (100 mg)
Number of subjects: 9
Study 14668079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10960378 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine containing epinephrine 0.5 microg/kg IV
Number of subjects: 100
Study 10960378 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine containing isoproterenol 0.1 microg/kg
Number of subjects: 100
Study 10960378 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study 10960378 — intervention group
Group type: COMPARATOR
Intervention: Saline pretreatment followed by the lidocaine‐isoproterenol test dose
Number of subjects: 100
Study 10960378 — intervention group
Group type: COMPARATOR
Intervention: Saline followed by saline
Number of subjects: 100
Study 8866274 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric isokinetic dynamometry
Number of subjects: 23
Study 8866274 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held dynamometry
Number of subjects: 23
Study 8866274 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric isokinetic dynamometry
Number of subjects: 23
Study 8866274 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric dynamometry
Number of subjects: 23
Study 8866274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain scores
Number of subjects: 23
Study 1497774 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective Structured Clinical Examination (OSCE)
Number of subjects: 240
Study 1497774 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexamination questionnaires given to physician examiners
Number of subjects: 240
Study 6704644 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 35
Study 6704644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 35
Study 6704644 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver Scintigraphy
Number of subjects: 35
Study 6704644 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 35
Study 31986103 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual biofeedback group (n = 12)
Number of subjects: 24
Study 31986103 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 24
Study 30813956 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-RO model
Number of subjects: 156
Study 30813956 — intervention group
Group type: COMPARATOR
Intervention: T-RO model
Number of subjects: 156
Study 30813956 — intervention group
Group type: COMPARATOR
Intervention: PT-E
Number of subjects: 156
Study 27613941 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific CBT
Number of subjects: 342
Study 27613941 — intervention group
Group type: COMPARATOR
Intervention: Standard CBT
Number of subjects: 342
Study 27245121 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 100
Study 25457355 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative yoga programme
Number of subjects: 20
Study 25457355 — intervention group
Group type: COMPARATOR
Intervention: Control group without treatment
Number of subjects: 20
Study 21892704 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (5 years)
Number of subjects: 746
Study 20973706 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 0
Study 20973706 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD symptoms
Number of subjects: 0
Study 20973706 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication satisfaction, ADHD symptoms, and HRQL
Number of subjects: 0
Study 20973706 — intervention group
Group type: EXPERIMENTAL
Intervention: Child HRQL
Number of subjects: 0
Study 20973706 — intervention group
Group type: EXPERIMENTAL
Intervention: Family HRQL
Number of subjects: 0
Study 17662509 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hospital diet plus 400 mL oral nutritional supplements (106 subjects)
Number of subjects: 225
Study 17662509 — intervention group
Group type: COMPARATOR
Intervention: Normal hospital diet plus placebo (119 subjects)
Number of subjects: 225
Study 16325695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (epirubicin, cyclophosphamide, and thiotepa supported by peripheral-blood progenitors)
Number of subjects: 403
Study 16325695 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (four cycles of epirubicin and cyclophosphamide followed by three cycles of accelerated cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 403
Study 11809427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 516
Study 11809427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 516
Study 11809427 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 516
Study 11809427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study 9642605 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (amoxicillin and erythromycin)
Number of subjects: 196
Study 9642605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 8090390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush and modified Ayers spatula
Number of subjects: 352
Study 8090390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervex‐Brush
Number of subjects: 352
Study 8090390 — intervention group
Group type: COMPARATOR
Intervention: Cotton swab and modified Ayers spatula
Number of subjects: 352
Study 2518867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg for 5 days)
Number of subjects: 10
Study 2518867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 793404 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betamethasone phosphate 0.1% eyedrops, five times daily for two weeks
Number of subjects: 107
Study 793404 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops, five times daily for two weeks
Number of subjects: 107
Study 31651246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal magnesium sulfate (25 mg in 0.5 ml saline)
Number of subjects: 105
Study 31651246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal dexmedetomidine (5 μg in 0.5 ml saline)
Number of subjects: 105